Oncodisc, Inc. Awarded Competitive Grant from the National Science Foundation to Develop Cancer Technology
WALNUT CREEK, Calif., Aug. 6, 2020 /PRNewswire/ — Oncodisc, Inc. today announced that it is the recipient of a competitive National Science Foundation (NSF) Small Business Innovation Research (SBIR) grant award. The grant award will be used to advance research and development work on the Oncodisc Remote Care Platform (“Oncodisc RCP”) and the development of next-generation patient care technology.
“Cancer care is the single most rapidly increasing component of US healthcare spending. More than 80% of that cancer care, including immunotherapy and chemotherapy, takes place in outpatient clinics,” said James Mitchell, MD, founder and CEO of Oncodisc, Inc. “We are pleased to work with the NSF on this important remote patient care technology to benefit the 17 million global patients diagnosed with cancer each year. Among the first to benefit will be the 9.8 million that require first-line chemotherapy and 7.4 million that are eligible for immunotherapy.”
“This funding will enable us to advance our AI-embedded intelligent implantable technology and support our mission to improve personalized cancer care through remote detection of changes in patient health status and streamlining doctor-patient communication. Our technology is applicable to other chronic diseases as well,” said Dr. Mitchell.
“NSF is proud to support the technology of the future by thinking beyond incremental developments and funding the most creative, impactful ideas across all markets and areas of science and engineering,” said Andrea Belz, Division Director of the Division of Industrial Innovation and Partnerships at NSF. “With the support of our research funds, any deep technology startup or small business can guide basic science into meaningful solutions that address tremendous needs.”
The Oncodisc RCP integrates physician-designed software, firmware, and the world’s first intelligent implantable vascular access port. The technology aims to provide an uninterrupted stream of digital biodata while facilitating immunotherapy, chemotherapy and integrating with existing oncology workflow.
Contacts:
James Mitchell, MD
Chief Executive Officer
Oncodisc
ceo@oncodisc.com
